The prevention of Lyme disease with vaccine

Gregory A. Poland, Robert M. Jacobson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Lyme disease is a potentially serious and debilitating infection caused by Borrelia burgdorferi that is endemic in North America, Europe, and Asia. Personal protective and environmental measures have not significantly impacted its increasing incidence. An adjuvanted recombinant vaccine (LYMErix™) has been approved in the United States for the prevention of Lyme disease in adults, and has demonstrated both safety and efficacy. A clinical trial of over 10 000 adults showed 76% efficacy following the third dose of a 0, 1, 12 schedule. Accelerated schedules demonstrate equivalent levels of protective antibody. Up to 100% of children 2-14 years of age achieve seroprotective levels of antibody. Booster doses induced protective levels of antibody in more than 96% of recipients when administered at months 12 and 24. Only mild or moderate, transient vaccine-associated adverse events have been reported after immunization. The vaccine is a safe and effective method of preventing Lyme disease.

Original languageEnglish (US)
Pages (from-to)2303-2308
Number of pages6
JournalVaccine
Volume19
Issue number17-19
DOIs
StatePublished - Mar 21 2001

Fingerprint

Lyme Disease Vaccines
Lyme disease
Lyme Disease
vaccines
antibodies
Antibodies
Appointments and Schedules
Vaccines
Northern Asia
Synthetic Vaccines
Borrelia burgdorferi
recombinant vaccines
dosage
North America
clinical trials
Immunization
immunization
Clinical Trials
Safety
incidence

Keywords

  • Borrelia burgdorferi
  • Lyme vaccine
  • OspA

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Poland, G. A., & Jacobson, R. M. (2001). The prevention of Lyme disease with vaccine. Vaccine, 19(17-19), 2303-2308. https://doi.org/10.1016/S0264-410X(00)00520-X

The prevention of Lyme disease with vaccine. / Poland, Gregory A.; Jacobson, Robert M.

In: Vaccine, Vol. 19, No. 17-19, 21.03.2001, p. 2303-2308.

Research output: Contribution to journalArticle

Poland, GA & Jacobson, RM 2001, 'The prevention of Lyme disease with vaccine', Vaccine, vol. 19, no. 17-19, pp. 2303-2308. https://doi.org/10.1016/S0264-410X(00)00520-X
Poland, Gregory A. ; Jacobson, Robert M. / The prevention of Lyme disease with vaccine. In: Vaccine. 2001 ; Vol. 19, No. 17-19. pp. 2303-2308.
@article{189dd6fa9efd4792aaea238bfe097e96,
title = "The prevention of Lyme disease with vaccine",
abstract = "Lyme disease is a potentially serious and debilitating infection caused by Borrelia burgdorferi that is endemic in North America, Europe, and Asia. Personal protective and environmental measures have not significantly impacted its increasing incidence. An adjuvanted recombinant vaccine (LYMErix™) has been approved in the United States for the prevention of Lyme disease in adults, and has demonstrated both safety and efficacy. A clinical trial of over 10 000 adults showed 76{\%} efficacy following the third dose of a 0, 1, 12 schedule. Accelerated schedules demonstrate equivalent levels of protective antibody. Up to 100{\%} of children 2-14 years of age achieve seroprotective levels of antibody. Booster doses induced protective levels of antibody in more than 96{\%} of recipients when administered at months 12 and 24. Only mild or moderate, transient vaccine-associated adverse events have been reported after immunization. The vaccine is a safe and effective method of preventing Lyme disease.",
keywords = "Borrelia burgdorferi, Lyme vaccine, OspA",
author = "Poland, {Gregory A.} and Jacobson, {Robert M.}",
year = "2001",
month = "3",
day = "21",
doi = "10.1016/S0264-410X(00)00520-X",
language = "English (US)",
volume = "19",
pages = "2303--2308",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17-19",

}

TY - JOUR

T1 - The prevention of Lyme disease with vaccine

AU - Poland, Gregory A.

AU - Jacobson, Robert M.

PY - 2001/3/21

Y1 - 2001/3/21

N2 - Lyme disease is a potentially serious and debilitating infection caused by Borrelia burgdorferi that is endemic in North America, Europe, and Asia. Personal protective and environmental measures have not significantly impacted its increasing incidence. An adjuvanted recombinant vaccine (LYMErix™) has been approved in the United States for the prevention of Lyme disease in adults, and has demonstrated both safety and efficacy. A clinical trial of over 10 000 adults showed 76% efficacy following the third dose of a 0, 1, 12 schedule. Accelerated schedules demonstrate equivalent levels of protective antibody. Up to 100% of children 2-14 years of age achieve seroprotective levels of antibody. Booster doses induced protective levels of antibody in more than 96% of recipients when administered at months 12 and 24. Only mild or moderate, transient vaccine-associated adverse events have been reported after immunization. The vaccine is a safe and effective method of preventing Lyme disease.

AB - Lyme disease is a potentially serious and debilitating infection caused by Borrelia burgdorferi that is endemic in North America, Europe, and Asia. Personal protective and environmental measures have not significantly impacted its increasing incidence. An adjuvanted recombinant vaccine (LYMErix™) has been approved in the United States for the prevention of Lyme disease in adults, and has demonstrated both safety and efficacy. A clinical trial of over 10 000 adults showed 76% efficacy following the third dose of a 0, 1, 12 schedule. Accelerated schedules demonstrate equivalent levels of protective antibody. Up to 100% of children 2-14 years of age achieve seroprotective levels of antibody. Booster doses induced protective levels of antibody in more than 96% of recipients when administered at months 12 and 24. Only mild or moderate, transient vaccine-associated adverse events have been reported after immunization. The vaccine is a safe and effective method of preventing Lyme disease.

KW - Borrelia burgdorferi

KW - Lyme vaccine

KW - OspA

UR - http://www.scopus.com/inward/record.url?scp=0035925636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035925636&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00520-X

DO - 10.1016/S0264-410X(00)00520-X

M3 - Article

C2 - 11257352

AN - SCOPUS:0035925636

VL - 19

SP - 2303

EP - 2308

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-19

ER -